Grazko M A, Polo K B, Jabbari B
Neurology Service, Walter Reed Army Medical Center, Washington, DC. 20307-5001, USA.
Neurology. 1995 Apr;45(4):712-7. doi: 10.1212/wnl.45.4.712.
We studied the effects of botulinum toxin A in 12 patients with spasticity and in eight patients with rigidity. The study design was a double-blind, placebo-controlled crossover trial with botulinum toxin A versus saline. Using the Ashworth Scale for spasticity and the Unified Parkinson's Disease Rating Scale for rigidity, we gave the patients a tone grade before and 2 weeks after treatment. Improvement in tone by two grades or more was considered clinically significant. In the spasticity group, botulinum toxin A reduced the tone of all patients significantly, improved functionality and nursing care in eight of 12 patients, and alleviated painful spasms in five of five patients. In the rigidity group, muscle tone was decreased in seven of eight patients, functionality improved in four of seven, and joint and muscle pain decreased in four of five. We conclude that botulinum toxin A is effective against the disabling effects of spasticity and rigidity. The treatment was well tolerated.
我们研究了A型肉毒杆菌毒素对12例痉挛患者和8例强直患者的影响。研究设计为双盲、安慰剂对照的交叉试验，比较A型肉毒杆菌毒素与生理盐水。使用Ashworth痉挛量表和统一帕金森病评定量表评估强直情况，我们在治疗前及治疗后2周对患者进行肌张力分级。肌张力改善两个级别或更多被认为具有临床意义。在痉挛组中，A型肉毒杆菌毒素显著降低了所有患者的肌张力，12例患者中有8例功能和护理得到改善，5例有疼痛性痉挛的患者中有5例症状缓解。在强直组中，8例患者中有7例肌张力下降，7例中有4例功能改善，5例中有4例关节和肌肉疼痛减轻。我们得出结论，A型肉毒杆菌毒素对痉挛和强直的致残作用有效。该治疗耐受性良好。
